Nkarta, Inc. (NKTX)
Nasdaq · Healthcare · Biotechnology
$2.53−1.75%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $181M
- 52-week range
- $1.70 – $3.72
- 52-week change
- +25.00%
- EPS (trailing)
- −$1.58
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$104M
- Diluted EPS
- −$1.41
- Free cash flow
- −$89.9M
From the company’s annual report on SEC EDGAR.
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Headquarters: South San Francisco, United States · 106 employees · nkartatx.com